The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Patients with BRCA mutations often face aggressive disease and poor prognosis
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
